Background:Mineral and bone disorder is one of the severe complications in kidney transplant recipients (KTRs).Previous studies showed that bisphosphonates had favorable effects on bone mineral density (BMD).We sought to compare different bisphosphonate regimens and rank their strategies.Methods:We searched PubMed,Embase,and the Cochrane Central Register of Controlled Trials (CENTRAL) up to April 01,2017,for randomized controlled trials (RCTs) comparing bisphosphonate treatments in adult KTRs.The primary outcome was BMD change.We executed the tool recommended by the Cochrane Collaboration to evaluate the risk of bias.We performed pairwise meta-analyses using random effects models and network meta-analysis (NMA) using Bayesian models and assessed the quality of evidence.Results:A total of 21 RCTs (1332 participants) comparing 6 bisphosphonate regimens were included.All bisphosphonates showed a significantly increased percentage change in BMD at the lumbar spine compared to calcium except clodronate.Pamidronate with calcium and Vitamin D analogs showed improved BMD in comparison to clodronate with calcium (mean difference [MD],9.84;95％ credibility interval [CrI],1.06-19.70).The combination of calcium and Vitamin D analogs had a significantly lower influence than adding either pamidronate or alendronate (MD,6.34;95％ CrI,2.59-11.01 and MD,6.16;95％ CrI,0.54-13.24,respectively).In terms of percentage BMD change at the femoral neck,both pamidronate and ibandronate combined with calcium demonstrated a remarkable gain compared with calcium (MD,7.02;95％ CrI,0.30-13.29 and MD,7.30;95％ CrI,0.32-14.22,respectively).The combination of ibandronate with calcium displayed a significant increase in absolute BMD compared to any other treatments and was ranked best.Conclusions:Our NMA suggested that new-generation bisphosphonates such as ibandronate were more favorable in KTRs to improve BMD.However,the conclusion should be treated with caution due to indirect comparisons.